Bill Clarke

XLock is built on the vision that chemokine biology holds the key to next-generation precision therapies in immunology and oncology. By applying deep expertise in protein engineering and immune system modulation, we are exploring new ways to selectively target disease-driving pathways. ‍ Our chemokine-targeting platform is designed to enhance specificity, reduce off-target effects, and expand the potential of precision medicine.